James Edgemond compensation by year
UNITED THERAPEUTICS Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $591,014 | $620,833 | $645,833 | $645,192 | $722,115 | $721,154 | $745,192 | $790,385 | $860,577 | $955,769 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1,505,100 | $2,440,323 | $1,950,974 |
| Option awards | $2,097,315 | $6,583,317 | $3,382,085 | $13,003,250 | $0 | $0 | $0 | $1,659,590 | $2,578,007 | $1,953,133 |
| Non-equity incentive | $360,000 | $577,148 | $731,250 | $632,813 | $677,250 | $679,688 | $1,243,181 | $1,331,520 | $1,968,750 | $1,616,063 |
| Pension and deferred compensation | $1,039,675 | $854,747 | $467,161 | $1,668,041 | $1,790,415 | $481,573 | $0 | $741,821 | $1,282,437 | $1,849,381 |
| All other | $21,450 | $17,000 | $16,400 | $19,600 | $20,000 | $20,800 | $17,411 | $26,068 | $34,455 | $23,047 |
| Total | $4,109,454 | $8,653,045 | $5,242,729 | $15,968,896 | $3,209,780 | $1,903,215 | $2,005,784 | $6,054,484 | $9,164,549 | $8,348,367 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UNITED THERAPEUTICS Corp DEF 14A filed April 29, 2026, accession 0001082554-26-000009, and prior-year filings. Open the filing on EDGAR.
How this page was built: the UNITED THERAPEUTICS Corp filed document, accession 0001082554-26-000009. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 15,525 | $7,564,556 | — |
| RSU | 10,380 | $5,057,655 | — |
| RSU | 9,525 | $4,641,056 | — |
| RSU | 9,098 | $4,433,001 | — |
| Option | 53,340 | — | $307.24 |
| Option | 79,470 | — | $235.78 |
| Option | 58,170 | — | $217.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in UNITED THERAPEUTICS Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
210 Form 4 lines since the FY2025 proxy (filed April 29, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-22 | Sale | 10b5-1 | 1,994 | $539.13 | 20,406 |
| 2026-06-22 | Sale | 10b5-1 | 164 | $534.06 | 27,462 |
| 2026-06-22 | Sale | 10b5-1 | 2,266 | $538.23 | 22,400 |
| 2026-06-22 | Sale | 10b5-1 | 865 | $534.98 | 26,597 |
| 2026-06-22 | Exercise or conversion derivative | 10b5-1 | 8,750 | $0.00 | 0 |
| 2026-06-22 | Sale | 10b5-1 | 1,250 | $541.25 | 18,876 |
| 2026-06-22 | Sale | 10b5-1 | 280 | $539.83 | 20,126 |
| 2026-06-22 | Exercise or conversion | 10b5-1 | 8,750 | $146.03 | 27,626 |
The 8 most recent of 210 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
UNITED THERAPEUTICS’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Martine Rothblatt | Chairperson and Chief Executive Officer | $18,038,972 |
| Michael Benkowitz | President and Chief Operating Officer | $14,385,655 |
| James Edgemond · this page | Chief Financial Officer and Treasurer | $8,348,367 |
| Paul Mahon | Executive Vice President and General Counsel | $5,531,313 |
James Edgemond's compensation dossier, UNITED THERAPEUTICS
You have read James Edgemond's totals and holdings. The dossier adds each equity grant UNITED THERAPEUTICS disclosed for James Edgemond and UNITED THERAPEUTICS's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full UNITED THERAPEUTICS compensation record
free company briefThis page is one person within UNITED THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the UNITED THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order UNITED THERAPEUTICS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UNITED THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order UTHR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.